Loading...
Docoh

OncoSec Medical (ONCS)

OncoSec Medical Incorporated is a late-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate - TAVO™ (tavokinogene telseplasmid) - enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions.

Company profile

Ticker
ONCS
Exchange
Website
CEO
Daniel O'Connor
Employees
Incorporated
Location
Fiscal year end
Former names
NetVentory Solutions, Inc.
SEC CIK
IRS number
980573252

ONCS stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 Jun 22
12 Aug 22
31 Jul 23
Quarter (USD) Apr 22 Jan 22 Oct 21 Jul 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Jul 21 Jul 20 Jul 19 Jul 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 19.48M 19.48M 19.48M 19.48M 19.48M 19.48M
Cash burn (monthly) 1.92M 2.91M 3.19M 3.63M 1.78M 2.8M
Cash used (since last report) 6.62M 10.04M 11.03M 12.55M 6.14M 9.67M
Cash remaining 12.86M 9.43M 8.45M 6.93M 13.33M 9.8M
Runway (months of cash) 6.7 3.2 2.6 1.9 7.5 3.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
5 Aug 22 DelAversano Robert J Common Stock Sell Dispose S No No 0.71 284 201.64 23,258
6 May 22 DelAversano Robert J Common Stock Sell Dispose S No No 0.83 274 227.42 23,542
2 May 22 Robert H. Arch Stock Option Common Stock Grant Acquire A No No 0.84 700,000 588K 700,000
43.2% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 31 38 -18.4%
Opened positions 1 8 -87.5%
Closed positions 8 6 +33.3%
Increased positions 7 8 -12.5%
Reduced positions 10 10
13F shares Current Prev Q Change
Total value 36.31M 35.53M +2.2%
Total shares 17M 17.24M -1.4%
Total puts 0 0
Total calls 0 76.4K EXIT
Total put/call ratio
Largest owners Shares Value Change
China Grand Pharmaceutical & Healthcare 10M $18.6M 0.0%
Avidity Partners Management 2.95M $3.39M 0.0%
Alpha 1.72M $11.63M 0.0%
Vanguard 731.52K $842K 0.0%
BK Bank Of New York Mellon 386.07K $444K +653.7%
Salzhauer Michael 296.28K $341K -7.8%
Geode Capital Management 271.48K $312K +3.4%
BLK Blackrock 95.36K $110K -3.2%
Tocqueville Asset Management 75.5K $87K 0.0%
Long Focus Capital Management 69.23K $80K 0.0%
Largest transactions Shares Bought/sold Change
BK Bank Of New York Mellon 386.07K +334.85K +653.7%
Two Sigma Advisers 0 -221.57K EXIT
Renaissance Technologies 49K -200.36K -80.4%
Highland Capital Management Fund Advisors 0 -75K EXIT
Two Sigma Securities 0 -35.08K EXIT
Sandbox Financial Partners 27.5K -35K -56.0%
Salzhauer Michael 296.28K -25.07K -7.8%
Susquehanna International 66.19K +22.12K +50.2%
Citadel Advisors 29.11K -11.22K -27.8%
Two Sigma Investments 0 -10.4K EXIT

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: appointed, appointment, Arch, confirmed, Dr, employed, Group, incumbent, installment, Joon, Kim, misleading, occasionally, policy, salary
Removed: Allergy, close, developed, feedback, immunogenic, IND, intend, Joseph, National, NIAID, outcome, population, prevent, prophylactic, return, SBA, St, vaccine

Patents

Utility
Systems and methods for improved tissue-sensing based electroporation
3 May 22
An adaptive control method for controlling EP pulse parameters during electroporation (EP) of cells or tissue using an EP system includes providing a system for adaptive control to optimize EP pulse parameters including EP pulse parameters, applying voltage and current excitation signals to the cells, obtaining data from the current and voltage measurements, and processing the data to separate the desirable data from the undesirable data, extracting relevant features from the desirable data, applying at least a portion of the relevant features to a trained diagnostic model, estimating EP pulsing parameters based on an outcome of the applied relevant features, where the initialized EP pulsing parameters are based on the trained model and the relevant features, to optimize the EP pulsing parameters, and applying, by the generator, a first EP pulse based on the first pulsing parameters.
Utility
Multigene Construct for Immune-modulatory Protein Expression and Methods of Use
10 Feb 22
Provided are expression vector constructs encoding IL-12 p35 and IL-12 p40 proteins where each protein or component thereof can be expressed utilizing appropriate promoters and/or translation modifiers.
Utility
Plasmid Constructs for Treating Cancer and Methods of Use
10 Feb 22
Described are expression cassettes encoding CD3-half-BiTE, CXCL9 and CTLA-4 scFv.
Utility
CorrectedModulating Responses to Checkpoint Inhibitor Therapy
2 Dec 21
The present invention provides for a dosing schedule for the intratumoral delivery of an immunostimulatory cytokine in combination with systemic delivery of a checkpoint inhibitor.
Utility
Systems and Methods for Detecting Fault Conditions In Electroporation Therapy
18 Nov 21
Example systems, apparatuses, methods, and computer program products are disclosed for electroporating cells in a tissue using a set of voltage pulses generated by capacitor charge circuitry based on a voltage supply.